Extended Spectrum Beta-lactamases (ESBL) in Escherichia Coli and Klebsiella Pneumoniae: Trends in the Hospital and Community Settings
Overview
Affiliations
Background: To assess the prevalence of extended spectrum beta-lactamase (ESBL) producing Escherichia coli and Klebsiella strains in nosocomial and community-acquired infections.
Methodology: The study was conducted at a centralized microbiology laboratory in the Eastern Province of Saudi Arabia. Laboratory records (January 2004 - December 2005) were assessed. Associated resistance to a panel of antibiotics was determined.
Results: A total of 6,750 Gram-negative organisms were assessed for ESBL-phenotype. ESBL was detected in 6% (409/6,750) of isolates, the majority of which were E. coli (83%). ESBL producers were significantly higher among isolates from in-patients 15.4% (143/927) versus out-patients (4.5%; 266/5,823); p < 0.05. Old age (older than 60 years) represented a significant risk for having an ESBL-producing pathogen. Urine was the major source of ESBL isolates in in-patients (46.1%) and out-patients (74.4%). The proportion of urinary E. coli isolates which were ESBL producers was significantly higher among in-patients (53/506; 10.4%) compared to out-patients (182/4,074; 4.4%); p<0.05. Old age (older than 60 years) represented a significant risk for having an ESBL-producing pathogen. Urine was the major source of ESBL isolates in in-patients (46.1%) and out-patients (74.4%). The proportion of urinary E. coli isolates which were ESBL producers was significantly higher among in-patients (53/506; 10.4%) compared to out-patients (182/4,074; 4.4%); p<0.05. Among in-patients, 60% of the ESBL associated infections were nosocomial. All were sensitive to imipenem but high levels of resistance to gentamicin, amikacin, amoxicillin-clavulanic acid and ciprofloxacin was shown.
Conclusion: The findings document evidence of the spread of multiresistant ESBL-producers into the community. This has significant implications for patient management, and indicates the need for increased surveillance and molecular characterization of these isolates.
Alameer K, Abuageelah B, Alharbi R, Alfaifi M, Hurissi E, Haddad M Health Sci Rep. 2025; 8(1):e70378.
PMID: 39867706 PMC: 11757819. DOI: 10.1002/hsr2.70378.
Endalamaw K, Tadesse S, Asmare Z, Kebede D, Erkihun M, Abera B BMC Microbiol. 2024; 24(1):525.
PMID: 39695370 PMC: 11657465. DOI: 10.1186/s12866-024-03693-8.
Prevalence of carbapenem-resistant (CRE) in Saudi Arabia: A systematic review and meta-analysis.
Alshehri A, Irekeola A Saudi Pharm J. 2024; 32(11):102186.
PMID: 39498344 PMC: 11532984. DOI: 10.1016/j.jsps.2024.102186.
Sampah J, Owusu-Frimpong I, Aboagye F, Owusu-Ofori A PLoS One. 2023; 18(10):e0274156.
PMID: 37903118 PMC: 10615269. DOI: 10.1371/journal.pone.0274156.
Ullah N, Assawakongkarat T, Akeda Y, Chaichanawongsaroj N Sci Rep. 2023; 13(1):12022.
PMID: 37491387 PMC: 10368679. DOI: 10.1038/s41598-023-39228-w.